Safety and efficacy of nivolumab and ipilimumab compared to nivolumab monotherapy in advanced unresectable cancers : a systematic review and meta analysis of randomized controlled trials
Year: 2026
Type: article
Study designs: Systematic Review, Meta-Analysis
Abstract: Advanced unresectable malignancies are associated with significant global morbidity and mortality. While immune checkpoint inhibitors have revolutionized treatment, the optimal use of dual-agent blockade compared to monotherapy remains a subject of investigation. This systematic review and meta-analysis evaluates the efficacy and safety of nivolumab plus ipilimumab (I + N) versus nivolumab (N) monotherapy across diverse solid tumors, focusing on the impact of dosing regimens and PD-L1 expression. We searched PubMed, Scopus, Cochrane Library, and Web of Science through February 2026 for RCTs comparing I + N to N monotherapy in patients with advanced solid tumors. Primary outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and Grade ≥ 3 treatment-related adverse events (TRAEs). Data were pooled using random-effects models, with results reported as hazard ratios (HR) or risk ratios (RR). Sixteen studies were included. Compared with nivolumab monotherapy, the NIVO3 + IPI1 regimen significantly improved progression-free survival (HR 0.79, 95% CI 0.65–0.94), overall survival (HR 0.79, 95% CI 0.70–0.90), and objective response rate (RR 1.19, 95% CI 1.07–1.33). However, combination therapy was associated with increased grade ≥ 3 treatment-related adverse events (TRAEs) (RR 1.41, 95% CI 1.19–1.67), treatment discontinuation (RR 2.64, 95% CI 2.03–3.44), whereas the increase in treatment-related mortality was not statistically significant (RR 2.55, 95% CI 0.93–6.96). Compared with nivolumab monotherapy, the NIVO1 + IPI3 regimen demonstrated a significantly higher objective response rate (RR 1.49, 95% CI 1.20–1.84) but was also associated with increased grade ≥ 3 TRSAEs (RR 3.43, 95% CI 1.84–6.38). The predictive value of PD-L1 expression was heterogeneous across tumor types. Stronger associations between PD-L1 positivity and improved efficacy were observed in urothelial, esophagogastric, and mesothelioma cohorts, whereas clinically meaningful activity regardless of PD-L1 status was reported in melanoma, NSCLC, SCLC, and colorectal cancer. Conclusion: Dual checkpoint blockade improves efficacy outcomes across advanced solid tumors but at the cost of substantially increased toxicity, with PD-L1 status showing inconsistent predictive value across tumor types.
Source: BMC Cancer
Institutions: University of Algiers Benyoucef Benkhedda, Al-Azhar University, Near East University, Tanta University, Jordan University of Science and Technology, Ain Shams University, Cairo University, Université Djilali de Sidi Bel Abbès, University of Science and Technology Omdurman, Alexandria University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: nivolumab, ipilimumab, dual immune checkpoint blockade, PD-1/PD-L1 inhibitors, PD-L1 expression, advanced solid tumors, progression-free survival, overall survival, objective response rate, treatment-related adverse events, dosing regimen, treatment discontinuation, non-relapse mortality, predictive biomarkers, immune-related adverse events, immunotherapy safety and efficacy
Open Access status: gold
Estimated APC paid: $3,390
OpenAlex ID: W7234783578
